テキサスにおける横紋筋肉腫の臨床試験
テキサス内の拠点で、横紋筋肉腫に関する9件の研究が参加者を募集しています。
テキサス内の都市
公式研究テキスト（英語）
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
- University of Texas - MD Anderson Cancer Center, Houston
被験者募集中第1相
24 Months – 18 Years · 全性別 · 2026/09/25更新 · NCT06441331Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- Children's Medical Center, Dallas
被験者募集中第1/2相
30歳以下 · 全性別 · 2026/09/03更新 · NCT06541262A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- 他2件
被験者募集中第3相
50歳以下 · 全性別 · 2026/08/25更新 · NCT07466316Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
- Texas Children's Hospital, Houston
被験者募集中第1相
1歳〜21歳 · 全性別 · 2026/08/06更新 · NCT04715191PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
- Texas Children's Hospital, Houston
被験者募集中第1/2相
1歳〜30歳 · 全性別 · 2026/07/22更新 · NCT06721689Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
- Cook Children's Medical Center, Fort Worth
被験者募集中第2相
22歳以下 · 全性別 · 2026/06/15更新 · NCT06023641VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
- The University of Texas Southwestern Medical Center, Dallas
- Texas Children's Hospital, Houston
被験者募集中第1/2相
6 Months – 30 Years · 全性別 · 2026/06/02更新 · NCT04796012HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
- Texas Children's Hospital, Houston
被験者募集中第1相
1歳〜25歳 · 全性別 · 2026/01/22更新 · NCT04995003Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
- Houston Methodist Hospital, Houston
被験者募集中第1相
21歳以下 · 全性別 · 2025/11/03更新 · NCT06198296ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。